Skip to main content
63°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vaccinex, Inc.
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
August 14, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
July 31, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
July 17, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
June 06, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
April 02, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 27, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
February 21, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
February 07, 2024
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
December 04, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
October 26, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
October 31, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Pricing of $9.6 Million Public Offering
September 28, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
September 28, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
September 27, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer
September 26, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. Announces Reverse Stock Split
September 22, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
June 01, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
April 25, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
April 12, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Private Placement with Commitments of $5.0 Million
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
April 03, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 23, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
March 21, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
March 09, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
VCNX
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
January 09, 2023
From
Vaccinex, Inc.
Via
GlobeNewswire
Tickers
SURF
VCNX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.